Glazer and Omer Are New Members of National Academy of Medicine
Two Yale faculty members, Peter M. Glazer, MD, PhD; and Saad B. Omer, MBBS, MPH, PHD; have been elected to the prestigious National Academy of Medicine, the academy announced today. Founded in 1970 as the Institute of Medicine the National Academy of Medicine (NAM) is one of three academies that make up the National Academies of Sciences, Engineering, and Medicine (the National Academies) in the United States.
Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Yale Study Shows Immunotherapy Drug Helps Patients with Metastatic Melanoma
When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. A study by Yale Cancer Center researchers published today in the Journal of Clinical Oncology (JCO) shows a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients. The study is one of the first clinical trials aimed at treating the brain metastases with this type of cancer drug.
Discovery may help provide clues for fighting and treating HPV
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. Their findings, published online today in the journal Cell, may eventually help to broaden the scope of defenses against HPV and provide valuable clues for delivering drugs into cells. HPV is a family of killers. Although there are effective vaccines against these viruses, they still cause about 5% of cancer deaths worldwide, including more than 250,000 women who die of cervical cancer each year.
Cancer patients who use alternative medicine die sooner, study finds
Cancer patients who choose alternative medicine over standard, proven cancer treatments are more likely to die, researchers reported Thursday. Complementary medicine did no apparent harm if people used it alongside conventional surgery, chemotherapy and radiation, the researchers found. But when people opted out of proven treatments to choose herbs, homeopathy or other alternative treatments, they were twice as likely to die of their cancer. “It’s shocking, the lack of comparative data that’s out there,” said Dr. James Yu of the Yale Cancer Center.Source: NBC News
Yale Cancer Researchers Suggest New Treatment for Rare Inherited Cancer
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests a promising strategy for treatment with drugs recently approved for other forms of cancer.
Mystery of breast cancer risk gene solved, 20 years after its discovery
More than 20 years after scientists revealed that mutations in the BRCA1 gene predispose women to breast cancer, Yale scientists have pinpointed the molecular mechanism that allows those mutations to wreak their havoc. The findings, reported Oct. 4 in the journal Nature, will not only help researchers design drugs to combat breast and ovarian cancers, but also help identify women who are at high risk of developing them, the authors say. “There have been about 14,000 papers written about BRCA1, and you would think we already know everything about the gene, but we don’t,” said senior author Patrick Sung, professor of molecular biophysics and biochemistry and of therapeutic radiology and member of the Yale Cancer Center.
Using alternative medicine only for cancer linked to lower survival rate
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center. The findings were reported online by the Journal of the National Cancer Institute.
How you can impact cancer research
Money raised at the American Cancer Society Relay for Life impacts programs for cancer patients — research for new treatments and a cure. It was a lifeline for Dr. Ranjit Bindra at Yale Cancer Center. He says, “The grant came at a time when our lab was desperately in need of funding. We were just getting started.” Dr. Bindra was just getting started, using radiation sensitizers for primary brain tumors – aimed at extending survival rate. “In many cases the overall survival for patients diagnosed with a primary brain tumor such as glioblastoma is maybe 12-14 months.” Most brain tumors regrow at the same site. This cutting edge approach focuses on preventing the tumor from returning. A drug, currently approved for high blood pressure, is at the center of it.Source: WTNH
Yale researcher gets $792,000 grant from cancer society
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding of a new research grant totaling $792,000 to a researcher at Yale University. The grant is among 109 national research and training grants totaling more than $45 million that will fund investigators at 75 institutions across the United States; 102 are new grants while seven are renewals of previous grants. The grants go into effect July 1. Ryan B. Jensen, Assistant Professor of Therapeutic Radiology at Yale School of Medicine, will begin work on his project titled, “Elucidating Cancer Risk in Homology-Directed Repair Variants.” According to a news release from the cancer society, Jensen’s lab is working to understand how failures in DNA repair contribute to both cancer risk and improved treatment strategies.Source: CT Post
Popular Prostate Cancer Therapy is Short, Intense, and Unproven
Stereotactic body radiotherapy (SBRT) is a promising treatment for prostate cancer, and involves 5 treatments (instead of more than 40). However, the treatment is still unproven. A randomized trial is being designed to answer the question, "How fast is too fast?"Source: The New York Times
Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer
Researchers at Yale think they've come up with a new way to treat a certain kind of brain tumor using a drug that's already been approved by the FDA. In a study published Wednesday in the journal Science Translational Medicine, the researchers outline a hypothesis for using the drug to tackle brain cancer. Thing is, the hypothesis they put forward is the exact opposite of the one other scientists, as well as several drug companies including Agios Pharmaceuticals, had previously been working with. The drug they discuss, called a PARP inhibitor, blocks a protein our cells use to repair DNA and kill off tumors. In certain kinds of cancer, that repair system is broken, which allows cancer cells to thrive.Source: Yahoo Finance